These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24640466)

  • 21. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions.
    Chodock R; Yolkut D; Connolly DR
    Tort Trial Insur Pract Law J; 2005; 40(3):997-1017. PubMed ID: 16100814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Marketing nutrition & health-related benefits of food & beverage products: enforcement, litigation & liability issues.
    Roller S; Pippins R
    Food Drug Law J; 2010; 65(3):447-69, i. PubMed ID: 24479235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Product liability and prescription diet drug cocktail, Fen-Phen: a hard combination to swallow.
    Crisanti CA
    J Contemp Health Law Policy; 1998; 15(1):207-44. PubMed ID: 9988998
    [No Abstract]   [Full Text] [Related]  

  • 24. Unapproved drugs in the United States and the Food and Drug Administration.
    Nasr A; Lauterio TJ; Davis MW
    Adv Ther; 2011 Oct; 28(10):842-56. PubMed ID: 21894470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deadly dimethylamylamine: "health" supplements are killing consumers while current regulations impede FDA action.
    Palmer PG
    J Leg Med; 2014; 35(2):311-36. PubMed ID: 24896317
    [No Abstract]   [Full Text] [Related]  

  • 26. The "natural" aversion: the FDA's reluctance to define a leading food-industry marketing claim, and the pressing need for a workable rule.
    Farris AL
    Food Drug Law J; 2010; 65(2):403-24, iv. PubMed ID: 24475548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renovations Needed: the FDA's Floor/Ceiling Framework, Preemption, and the Opioid Epidemic.
    Abrams MR
    Mich Law Rev; 2018 Oct; 117(1):143-71. PubMed ID: 30300989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cloned animal products in the human food chain: FDA should protect American consumers.
    Butler JE
    Food Drug Law J; 2009; 64(3):473-501. PubMed ID: 19999640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The FDA's reaction to corporate compliance audits.
    Shroff AP
    Food Drug Law J; 1996; 51(2):221-3. PubMed ID: 11820199
    [No Abstract]   [Full Text] [Related]  

  • 31. A hard look at FDA's review of GRAS notices.
    Roberts A; Haighton LA
    Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 2():S124-8. PubMed ID: 27318099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The (near) irrelevance of Daubert to criminal justice and some suggestions for reform.
    Neufeld PJ
    Am J Public Health; 2005; 95 Suppl 1():S107-13. PubMed ID: 16030325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importing a change in diet: the proposed food safety law of 2010 and the possible impact on importers and international trade.
    May SG
    Food Drug Law J; 2010; 65(1):1-35, i. PubMed ID: 24475533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Buckman extended: federal preemption of state fraud-on-the-FDA statutes.
    Gaddis CA
    Food Drug Law J; 2014; 69(1):113-36, iii. PubMed ID: 24772688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medical devices; preemption of state product liability claims--FDA. Withdrawal of proposed rule.
    Fed Regist; 1998 Jul; 63(142):39789-90. PubMed ID: 10181516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing supplement safety--the FDA's controversial proposal.
    Cohen PA
    N Engl J Med; 2012 Feb; 366(5):389-91. PubMed ID: 22276780
    [No Abstract]   [Full Text] [Related]  

  • 38. Medical devices; preemption of state product liability claims--FDA. Proposed rule.
    Fed Regist; 1997 Dec; 62(239):65384-8. PubMed ID: 10176832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preemption of the "fraud on the FDA" exception to Michigan's tort immunity statute for drug manufacturers: reconsidering Garcia and Desiano after Levine.
    Murdey J
    Food Drug Law J; 2011; 66(1):85-104, ii-iii. PubMed ID: 24505848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Highlights and a hidden hazard--the FDA's new labeling regulations.
    Avorn J; Shrank W
    N Engl J Med; 2006 Jun; 354(23):2409-11. PubMed ID: 16760439
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.